<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094247</url>
  </required_header>
  <id_info>
    <org_study_id>MMPUFA17</org_study_id>
    <nct_id>NCT03094247</nct_id>
  </id_info>
  <brief_title>Feeding Malnourished Children Different Types of Fatty Acids to Promote Neurocognitive Development</brief_title>
  <official_title>Improved Polyunsaturated Ready-to-use Therapeutic Food for Improved Neurocognitive Outcomes in Severe Acute Malnutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malawi College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An appropriate balance of omega-6 and omega-3 fatty acids is important for support of
      neurocognitive development in healthy infants and toddlers. In young children recovering from
      severe acute malnutrition (SAM), excess omega-6 intake depletes omega-3 fatty acid status.
      This research will evaluate how novel ready-to-use therapeutic foods (RUTF) with balanced
      fatty acids improve the metabolic and neurocognitive effects in young children in Malawi
      recovering from SAM, yielding new knowledge that also has implications for development of
      well-nourished children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutritional recovery</measure>
    <time_frame>Up to 12 weeks following enrollment</time_frame>
    <description>Defined by resolution of edema AND mid-upper arm circumference [MUAC] &gt;12.4cm, AND/OR a weight/height z-score [WHZ] &gt;3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive outcome</measure>
    <time_frame>Upon nutritional recovery obtained at 4-12 weeks</time_frame>
    <description>Defined by Willatts intention score adapted for field training</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recognition memory</measure>
    <time_frame>Upon nutritional recovery obtained at 4-12 weeks</time_frame>
    <description>Measured by relational visual memory task as defined as overall percentage looking at match</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attentional orienting speed</measure>
    <time_frame>Upon nutritional recovery obtained at 4-12 weeks</time_frame>
    <description>Measured by mean saccade latency to peripheral targets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intentionality, planning, and attentional control tasks</measure>
    <time_frame>Upon nutritional recovery obtained at 4-12 weeks</time_frame>
    <description>Measured by complex object retrieval, look duration, time spent in focused attention, passive inattention, and active inattention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive outcome</measure>
    <time_frame>Upon nutritional recovery at 3 years of age</time_frame>
    <description>Measured by score on the Malawian Developmental Assessment Test (MDAT)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>Severe Acute Malnutrition</condition>
  <arm_group>
    <arm_group_label>Conventional RUTF (C-RUTF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the control group for the study, which will receive the international standard of care therapeutic food. C-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High oleic RUTF (HO-RUTF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment provided to children randomized to this arm of the study includes nutritional content comparable to C-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA-supplemented HO-RUTF (D-HO-RUTF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>All patients with severe acute malnutrition will receive a course of amoxicillin.</description>
    <arm_group_label>Conventional RUTF (C-RUTF)</arm_group_label>
    <arm_group_label>High oleic RUTF (HO-RUTF)</arm_group_label>
    <arm_group_label>DHA-supplemented HO-RUTF (D-HO-RUTF)</arm_group_label>
    <other_name>Amoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HO-RUTF</intervention_name>
    <description>HO-RUTF: Milk, linseed oil, palm oil, white sugar, high oleic peanuts</description>
    <arm_group_label>High oleic RUTF (HO-RUTF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-HO-RUTF</intervention_name>
    <description>D-HO-RUTF: DHA, milk, linseed oil, palm oil, white sugar, high oleic peanuts</description>
    <arm_group_label>DHA-supplemented HO-RUTF (D-HO-RUTF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>C-RUTF</intervention_name>
    <description>C-RUTF: Milk, linseed oil, palm oil, white sugar, standard peanuts</description>
    <arm_group_label>Conventional RUTF (C-RUTF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6-59 months

          -  An acceptable appetite defined by the ability to consume 30 grams RUTF within 20
             minutes

          -  Mid Upper Arm Circumference &lt;11.5 cm, weight-for-height z-score &lt; -3, or bilateral
             pitting edema on the dorsum of the feet

        Exclusion Criteria:

          -  Participation in any other ongoing study or supplementary feeding program

          -  Children with a chronic medical condition, including cerebral palsy, static
             encephalopathy, congenital heart disease, gastrointestinal disease, or peanut allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Manary, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark J Manary, MD</last_name>
    <phone>+1 314 454 2341</phone>
    <email>manary@kids.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kenneth Maleta, MBBS</last_name>
    <phone>+256 018 719 111</phone>
    <email>ken.maleta@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Malawi College of Medicine</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Maleta, MBBS</last_name>
      <phone>+256 018 719 111</phone>
      <email>ken.maleta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Maleta, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chrissie Thawalawka, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malnutrition</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Polyunsaturated fatty acids</keyword>
  <keyword>Ready-to-use therapeutic foods</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Peanuts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Severe Acute Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

